- Report
- May 2026
- 150 Pages
Thailand
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Turkey
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
United Kingdom
From €4406EUR$4,850USD£3,804GBP
- Report
- April 2023
- 220 Pages
Global
From €3270EUR$3,600USD£2,823GBP
- Report
- June 2025
- 316 Pages
Global
From €4042EUR$4,450USD£3,490GBP
- Report
- September 2022
- 342 Pages
Global
From €8630EUR$9,500USD£7,450GBP
- Report
- June 2021
- 50 Pages
China
From €2362EUR$2,600USD£2,039GBP
- Report
- November 2024
- 89 Pages
Global
From €3500EUR$4,127USD£3,127GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,127USD£3,127GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,127USD£3,127GBP
- Report
- October 2023
- 94 Pages
Global
From €3500EUR$4,127USD£3,127GBP
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more